Ruxolitinib
- Generic Name
- Ruxolitinib
- Brand Names
- Jakafi, Jakavi, Opzelura
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N6
- CAS Number
- 941678-49-5
- Unique Ingredient Identifier
- 82S8X8XX8H
- Background
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...
- Indication
Ruxolitinib is indicated for the treatment of the following conditions:
Topical ruxolitinib is indicated for:
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera
- Associated Therapies
- -
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
- Conditions
- Interventions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Telios Pharma, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05280509
- Locations
- 🇮🇹
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy
🇮🇹Azienda Ospedaliera di Perugia-Ospedale S. Maria della Misericordia, Perugia, Italy
🇪🇸Hospital Quironsalud de Zaragoza, Zaragoza, Spain
MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera
- Conditions
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05269771
Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome
- Conditions
- Interventions
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05137496
Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease
- Conditions
- Interventions
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 13
- Registration Number
- NCT05121142
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
- Conditions
- Interventions
- Drug: Purified regulatory T-cells (Treg) plus CD34+ HSPCDrug: FludarabineDrug: TacrolimusDrug: MelphalanDevice: CliniMACS CD34 Reagent SystemDrug: PlerixaforDrug: Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalentDrug: ThiotepaDrug: CyclophosphamideDrug: Mycophenolate Mofetil (MMF)Drug: Ruxolitinib
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 40
- Registration Number
- NCT05088356
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
ECP Combination Study
- Conditions
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-03-28
- Target Recruit Count
- 319
- Registration Number
- NCT05052385
- Locations
- 🇧🇪
Antwerp University, Antwerp, Belgium
🇬🇷George Papanicolaou General Hospital, Thessaloníki, Greece
🇫🇷Institut de Cancerologie Lucien Neuwirth, Saint-Étienne, France
Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2021-08-25
- Target Recruit Count
- 50
- Registration Number
- NCT05021276
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT05010005
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Miami (Data Collection Only), Miami, Florida, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
- Conditions
- Interventions
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Xenikos
- Target Recruit Count
- 12
- Registration Number
- NCT04934670
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Mount Sinai Medical Center, New York, New York, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 330
- Registration Number
- NCT04921969
- Locations
- 🇺🇸
Ohio Pediatric Research Association, Dayton, Ohio, United States
🇺🇸Velocity Clinical Research Grants Pass Clinical Research Institute of Southern Oregon Pc, Grants Pass, Oregon, United States
🇺🇸Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.